Related references
Note: Only part of the references are listed.Vitamin B12 and Homocysteine Levels Predict Different Outcomes in Early Parkinson's Disease
Chadwick W. Christine et al.
MOVEMENT DISORDERS (2018)
Association of plasma homocysteine, vitamin B12 and folate levels with cognitive function in Parkinson's disease: A meta-analysis
Yi Xie et al.
NEUROSCIENCE LETTERS (2017)
Homocysteine and cognitive function in Parkinson's disease
Nicole Licking et al.
PARKINSONISM & RELATED DISORDERS (2017)
L-DOPA treatment in MPTP-mouse model of Parkinson's disease potentiates homocysteine accumulation in substantia nigra
Nivedita Bhattacharjee et al.
NEUROSCIENCE LETTERS (2016)
Homocysteine Levels in Parkinson's Disease: Is Entacapone Effective?
Bilge Kocer et al.
BIOMED RESEARCH INTERNATIONAL (2016)
Elevated homocysteine levels in levodopa-treated idiopathic Parkinson's disease: a meta-analysis
X. -W. Hu et al.
ACTA NEUROLOGICA SCANDINAVICA (2013)
Clinical significance of homocysteine (hcy) on dementia in Parkinson's disease (PD)
In-Uk Song et al.
ARCHIVES OF GERONTOLOGY AND GERIATRICS (2013)
Elevated Homocysteine by Levodopa Is Detrimental to Neurogenesis in Parkinsonian Model
Jin Young Shin et al.
PLOS ONE (2012)
Hyperhomocysteinemia recurrence in levodopa-treated Parkinson's disease patients
V. Belcastro et al.
EUROPEAN JOURNAL OF NEUROLOGY (2010)
L-Dopa therapy increases homocysteine concentration in cerebrospinal fluid from patients with Parkinson's disease
Chiaki Isobe et al.
JOURNAL OF CLINICAL NEUROSCIENCE (2010)
Cysteine Elevation in Levodopa-Treated Patients with Parkinson's Disease
Thomas Mueller et al.
MOVEMENT DISORDERS (2009)
Homocysteine Levels After Acute Levodopa Intake in Patients with Parkinson's Disease
Thomas Mueller et al.
MOVEMENT DISORDERS (2009)
Effect of levodopa and entacapone treatment on plasma homocysteine levels in Parkinson's disease patients
M. Nevrly et al.
PARKINSONISM & RELATED DISORDERS (2009)
Homocysteine is toxic for dopaminergic neurons in primary mesencephalic culture
Keiko Imamura et al.
NEUROREPORT (2007)
Vitamins and entacapone in levodopa-induced hyperhomocysteinemia: A randomized controlled study
RB Postuma et al.
NEUROLOGY (2006)
Plasma total homocysteine levels in a healthy Turkish population sample
G Taskin et al.
ACTA CARDIOLOGICA (2006)
Reduced plasma homocysteine levels in levodopa/entacapone treated Parkinson patients
P Valkovic et al.
PARKINSONISM & RELATED DISORDERS (2005)
Plasma homocysteine levels in Parkinson's disease: role of antiparkinsonian medications
S Zoccolella et al.
PARKINSONISM & RELATED DISORDERS (2005)
Effects of levodopa and COMT inhibitors on plasma homocysteine in Parkinson's disease patients
P Lamberti et al.
MOVEMENT DISORDERS (2005)
Elevated plasma homocysteine level in patients with Parkinson disease - Motor, affective, and cognitive associations
PE O'Suilleabhain et al.
ARCHIVES OF NEUROLOGY (2004)
Levodopa-induced hyperhomocysteinaemia in Parkinson's disease
K Yasui et al.
ACTA NEUROLOGICA SCANDINAVICA (2003)
Plasma homocysteine and malondialdehyde are correlated in an age- and gender-specific manner
RW Powers et al.
METABOLISM-CLINICAL AND EXPERIMENTAL (2002)
Homocysteine and risk of ischemic heart disease and stroke -: A meta-analysis
R Clarke et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2002)
Plasma homocysteine as a risk factor for dementia and Alzheimer's disease.
S Seshadri et al.
NEW ENGLAND JOURNAL OF MEDICINE (2002)
Dietary folate deficiency and elevated homocysteine levels endanger dopaminergic, neurons in models of Parkinson's disease
W Duan et al.
JOURNAL OF NEUROCHEMISTRY (2002)
Homocysteine and atherothrombosis - mechanisms for injury
J Thambyrajah et al.
EUROPEAN HEART JOURNAL (2000)
Share Paper
